67 /100
HIGH RISK
Score updated Jul 14, 2026

CVKD — Cadrenal Therapeutics, Inc. Dilution Risk Tracker

Track CVKD dilution risk with DilutionWatch's stock tracker. DilutionScore™ measures dilution risk across 5 factors — lower scores indicate higher risk of share dilution.

⚠️ Not financial advice. Do your own research before making any investment decisions.

🔔 Track CVKD — Get alerts when the score changes →

As of July 14, 2026, Cadrenal Therapeutics, Inc. (CVKD) has a DilutionWatch DilutionScore of 67/100, rated HIGH dilution risk. Cadrenal Therapeutics, Inc. has a market capitalization of $15.27M, 2.87M shares outstanding, 17 institutional holders tracked. Key dilution vectors include 18.6K outstanding warrants, approximately 2 months of cash runway.

Source: DilutionWatch (dilutionwatch.com) — data updated daily from SEC EDGAR filings. Not financial advice.

📊 Score Breakdown

📋 Offering Ability
66
💰 Cash Runway
95
📊 Float Risk
15
⚠️ Warrant Exposure
15
🔄Convertible Debt

🌦️ Dilution Forecast

🌥️
Advisory
Moderate dilution signals present
30%
💰 Capital Raise 55%
• Critical: only 2.5 months cash remaining
📉 Score Deterioration 10%
• Score in HIGH risk zone (67/100)
🔔 Track CVKD — Get forecast alerts →

💹 Market Data

Market Cap$15.27M
Shares Outstanding2.87M
Float2.38M
Cash$2.31M
Debt$597.1K
Short InterestN/A

🏛 Institutional Holdings

QoQ: ↑ 13.9% shares (2026Q1 vs prior)
17 institutional holders · 138.4K shares
#1 VANGUARD CAPITAL MANAGEMENT LLC 90.4K shares
#2 GEODE CAPITAL MANAGEMENT, LLC 21.6K shares
#3 VANGUARD FIDUCIARY TRUST CO 8.3K shares
+ 14 more holders Sign up free to view →

📉 Short Interest

Short Interest82.0K
Days to Cover1.2
% of Float3.4%
FINRA data as of Jun 30, 2026

📁 Recent SEC Activity

xbrl XBRL WARRANT Sep 30, 2025
xbrl XBRL CONVERTIBLE Dec 31, 2023
EFFECT EFFECT Apr 29, 2026
424B3 ATM Apr 29, 2026
S-3 SHELF Apr 21, 2026
Full SEC filing analysis available with free account

📰 Recent News

No recent news

📋 What This Means for CVKD Shareholders

Cadrenal Therapeutics, Inc. (CVKD) has a DilutionScore of 67/100, placing it in the High dilution risk tier. This score reflects at least one active dilution mechanism — a shelf registration, ATM program, outstanding warrants, or limited cash runway — that could materially increase the share count over the next 12–18 months. Score as of July 14, 2026, updated from SEC EDGAR data.

Cash runway is a key watch item: CVKD has approximately 2 months of runway at current burn rate. Companies with less than 18 months of runway are statistically more likely to file new shelf registrations or ATM programs within the next two quarters. DilutionWatch monitors SEC 10-Q filings to update this estimate each quarter.

DilutionWatch tracks over 25 SEC filing types for CVKD in real-time, scanning EDGAR every 60 seconds. A recent S-3 or registration statement filing appears in CVKD's filing history — this warrants monitoring for subsequent prospectus supplements (Form 424B), which indicate active capital raising. Recent 8-K filings are present; material events disclosures can sometimes precede or accompany capital raises. The DilutionWatch screener shows real-time score changes for CVKD alongside comparable high-risk stocks. Not financial advice — this analysis is for informational purposes only.

Track CVKD Dilution Risk in Real-Time
Get instant alerts when SEC filings impact dilution risk. Free tier available.
Start Tracking CVKD — Free
Real-time SEC alerts DilutionScore™ tracking No credit card required

🔗 Related Stocks — HIGH Risk

Other HIGH dilution risk stocks tracked by DilutionWatch with similar profiles:

Browse all 7,800+ tracked stocks →

📖 Dilution Education
→ Complete Dilution Guide for Retail Investors → Anti-Dilution Provisions Explained → Stock Dilution Red Flags to Watch → Understanding Shelf Registrations
🔬 More Research for CVKD
📊 CVKD FDA Catalyst Timeline & Biotech Grade — BiotechSigns 📡 CVKD Signal Convergence & Dark Pool Activity — StonkWhisper

Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.